MYCN Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant MYCN.
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, E |
---|---|
Primary Accession | P04198 |
Other Accession | NM_005378 |
Reactivity | Human |
Host | mouse |
Clonality | Monoclonal |
Isotype | IgG2a Kappa |
Clone Names | 3H4 |
Calculated MW | 49561 Da |
Gene ID | 4613 |
---|---|
Other Names | N-myc proto-oncogene protein, Class E basic helix-loop-helix protein 37, bHLHe37, MYCN, BHLHE37, NMYC |
Target/Specificity | MYCN (NP_005369, 1 a.a. ~ 100 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
Dilution | WB~~1:500~1000 |
Format | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
Storage | Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing. |
Precautions | MYCN Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene is a member of the MYC family and encodes a protein with a basic helix-loop-helix (bHLH) domain. This protein is located in the nucleus and must dimerize with another bHLH protein in order to bind DNA. Amplification of this gene is associated with a variety of tumors, most notably neuroblastomas.
References
Analysis of the REL, BCL11A, and MYCN proto-oncogenes belonging to the 2p amplicon in chronic lymphocytic leukemia. Deambrogi C, et al. Am J Hematol, 2010 Jul. PMID 20575024.Pleiotropic role for MYCN in medulloblastoma. Swartling FJ, et al. Genes Dev, 2010 May 15. PMID 20478998.Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma. Muth D, et al. Cancer Res, 2010 May 1. PMID 20424123.MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Foley NH, et al. Mol Cancer, 2010 Apr 21. PMID 20409325.Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor. Williams RD, et al. Clin Cancer Res, 2010 Apr 1. PMID 20332316.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.